All 19 Subjects in RepliCel’s Clinical Trial Complete Six-Month Follow-up
RepliCel Life Sciences Inc. is pleased to report that all 19 subjects have completed their six-month post injection follow-up visit and the company remains on schedule to release the initial review of efficacy results in April 2012. The data collected from the first six months following injection will be used for assessment of the primary safety and secondary safety and efficacy endpoints for the TS001-2009 clinical trial.
http://www.replicel.com/all-19-subje...llow-up-visit/